Physician profile
Daniel Varela
NPI 1508220054
$40,449.09
in general payments reported to CMS, 2019-2025
15 companies · $5,079 in 2025
The $5,079 reported for 2025 was more than what 92% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.06 · 2021: $296 · 2022: $9,840 · 2023: $16K · 2024: $9,173 · 2025: $5,079.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Grant: $8,898 · Travel and Lodging: $7,741 · Consulting Fee: $1,875 · Education: $359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,405.87 |
| Grant | $8,898.00 |
| Travel and Lodging | $7,741.18 |
| Consulting Fee | $1,875.00 |
| Education | $358.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $15,861.05 | 2021-2025 | Ensite Precision, Aveir, Ensite |
| Boston Scientific Corporation | $8,167.57 | 2022-2025 | Watchman Access System, Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Medtronic, INC. | $5,426.34 | 2022-2025 | Micra, Aurora Ev-Icd Mri Surescan, Selectsecure |
| Medical Device Business Services, INC. | $3,215.38 | 2022-2024 | Carto 3 |
| Biosense Webster, INC. | $2,727.25 | 2022-2025 | Carto 3, Qdot Micro Catheter, Qdot Micro |
| Altathera Pharmaceuticals LLC | $2,030.74 | 2024 | Sotalol Hydrochloride |
| Biotronik INC. | $1,125.17 | 2022-2025 | Acticor 7 Vr-T Dx, Amvia Edge, Rivacor 7 Dr-T |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $724.04 | 2022-2025 | Lifevest |
| Cardiva Medical, INC. | $394.62 | 2023-2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Astellas Pharma US INC | $198.00 | 2022 | |
| Atricure, INC. | $176.72 | 2024-2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Sanofi-Aventis U.S. LLC | $129.69 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $120.52 | 2023 | |
| Edwards Lifesciences Corporation | $79.62 | 2025 | Pascal |
| Abiomed | $72.38 | 2019-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Varela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.